Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 2/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.36 |
| ▸ | ACACB | O00763 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20147442 | 0.86 | ACACB (0.39) | RETACACBCHRM2CHRM3 | |
| SCHEMBL20069361 | 0.82 | CHRM4 (0.45) | HCRTR1HCRTR2CHRM2CHRM3 | |
| SCHEMBL20147464 | 0.79 | PDE3B (0.48) | HCRTR1HCRTR2RETCHRM2CHRM3 | |
| SCHEMBL21004583 | 0.79 | PDE3B (0.48) | HCRTR1HCRTR2RETCHRM2CHRM3 | |
| SCHEMBL25502832 | 0.78 | ADORA2A (0.44) | HCRTR1HCRTR2RETMCHR1ACACB | |
| SCHEMBL20152046 | 0.78 | ADORA2A (0.43) | HCRTR1HCRTR2MCHR1ACACB | |
| SCHEMBL20909894 | 0.77 | HCRTR1 (0.45) | HCRTR1HCRTR2MCHR1KCNH2 | |
| SCHEMBL29686659 | 0.76 | PIK3CD (0.52) | — | |
| SCHEMBL8511025 | 0.76 | MAPK14 (0.39) | MCHR1KCNH2 | |
| SCHEMBL20137746 | 0.76 | HCRTR1 (0.47) | HCRTR1HCRTR2ACACBCHRM3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10441581-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10441581-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | HCRTR1 2257/4885HCRTR2 3543/4885RET 1/4885 |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | HCRTR1 2257/4885HCRTR2 3543/4885RET 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.